The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock jumped, signaling a breakout.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.59, demonstrating a -1.4% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain ...

PRINCETON, N.J., September 10, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on ...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.